Opexa Therapeutics (OPXA) – Press Releases
-
Genexine Appoints Industry Veteran Neil Warma as Chief Executive Officer to Accelerate Global Growth, Product Commercialization and Innovation
-
I-Mab Biopharma Expands Global Team, Appoints Neil K. Warma As General Manager of I-Mab U.S.
-
Opexa Therapeutics, Inc. Urges Shareholders to Vote FOR the Merger with Acer Therapeutics; The Merger will Not Go Forward Unless ALL Proposals are Approved
-
Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Opexa Therapeutics Shareholders Vote "FOR" the Proposed Merger and Related Proposals
-
Opexa Therapeutics Reports Second Quarter 2017 Financial Results and Provides Corporate Update
-
Opexa Therapeutics to Present at Rodman & Renshaw 18th Annual Global Investment Conference
-
Opexa Therapeutics Reports Second Quarter 2016 Financial Results and Provides Corporate Update
-
Opexa Therapeutics Announces News Release and Conference Call Schedule to Discuss Second Quarter 2016 Financial Results
-
Opexa Therapeutics Reports First Quarter 2016 Financial Results and Provides Corporate Update
-
Opexa Therapeutics Announces News Release and Conference Call Schedule to Discuss First Quarter 2016 Financial Results
-
Opexa to Attend the Third International Conference on the Progress of Regenerative Medicine and Its Cultural Impact
-
Opexa Therapeutics Reports 2015 Year End Financial Results and Provides Corporate Update
-
Opexa Therapeutics Announces News Release and Conference Call Schedule to Discuss Year End 2015 Financial Results
-
Opexa Launches Restructuring Initiative to Focus Use of Resources Ahead of Key Phase 2 Data Expected in Early Q4 2016
-
Opexa Therapeutics to Present at the 18th Annual BIO CEO and Investor Conference
-
Opexa Therapeutics Chosen as One of the Top Autoimmune Therapy Projects to Watch
-
Opexa Therapeutics Announces Supportive Preclinical Study Results for its Neuromyelitis Optica (NMO) Program
-
Opexa Therapeutics Reports Third Quarter 2015 Financial Results and Provides Corporate Update
-
Opexa Therapeutics Announces News Release Schedule for Third Quarter 2015 Financial Results
-
Opexa Therapeutics to Host Analyst and Investor Event on November 10 in New York
-
Opexa Therapeutics Regains Compliance with NASDAQ Minimum Bid Price Listing Requirement
-
Opexa Therapeutics to Present at BIO Investor Forum
-
Opexa Announces Granting of New T-cell Patents Covering Tcelna®; Patent Estate Increases to 160 Issued Patents
-
Opexa Announces Reverse Stock Split
-
Taglich Brothers Initiates Coverage on Opexa Therapeutics, Inc.
-
Opexa Secures Private Funding for its NMO Orphan Development Program, Including Planned Phase I/II Clinical Study
-
Opexa Therapeutics to Present at September Conferences
-
Opexa Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update
-
Opexa Therapeutics Announces News Release and Conference Call Schedule to Discuss Second Quarter 2015 Financial Results
-
Rodman & Renshaw 2015 Annual Global Investment Conference to be held in New York from September 8 to 10, 2015
-
Opexa Therapeutics CEO to Present at BIO 2015 International Convention
-
Opexa Hires Experienced Pharmaceutical Executive as Vice President of Business Development
-
Opexa Therapeutics to Present at the 2015 Marcum Microcap Conference
-
Opexa Therapeutics CEO Invited to Participate in Multiple May Conferences
-
Opexa Therapeutics Reports First Quarter 2015 Financial Results and Provides Corporate Update
-
Opexa Therapeutics Announces News Release and Conference Call Schedule to Discuss First Quarter 2015 Financial Results
-
Opexa Therapeutics Invited to Present Biomarker Data from NMO Patients at The American Academy of Neurology (AAN) 2015 Annual Meeting
-
Opexa Therapeutics, Inc. Announces Completion of Rights Offering
-
Opexa Therapeutics Reminds Shareholders That Rights Offering Expires on April 8, 2015 at 5:00 PM ET
-
Opexa Therapeutics Reminds Shareholders That Rights Offering Ownership Date and Time is Tuesday, March 10, 2015 at 4:00 PM ET
-
Opexa Amends Agreement with Merck Serono and Receives Additional $3 Million Payment to Support Ongoing Development of Tcelna® for Multiple Sclerosis
Back to OPXA Stock Lookup
